Increased R&D spending results in larger loss for Edgewise
BOULDER — Clinical-stage, pre-revenue pharmaceutical company Edgewise Therapeutics Inc. (Nasdaq: EWTX), which markets itself as a developer of “orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders,” spent $19.9 million on research and development in the first quarter of 2023, up from $16.6 million for the immediately preceding period.
General and administrative expenses were also up slightly quarter over quarter.
Edgewise posted a net loss of $22.8 million in the most recent period, up from $19.4 million in the immediately preceding quarter.
SPONSORED CONTENT
Select your Republic Services residential cart now!
In preparation for Republic Services becoming the primary provider of residential recycling, yard trimmings, and trash, residents should now select the best cart size and service schedule for their household needs.
The company finished the first quarter of 2023 with cash, cash equivalents and marketable securities worth $328 million.
Edgewise’s stock price finished trading Thursday at $9.52, down 3.99% on the day.
BOULDER — Clinical-stage, pre-revenue pharmaceutical company Edgewise Therapeutics Inc. (Nasdaq: EWTX), which markets itself as a developer of “orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders,” spent $19.9 million on research and development in the first quarter of 2023, up from $16.6 million for the immediately preceding period.
General and administrative expenses were also up slightly quarter over quarter.
Edgewise posted a net loss of $22.8 million in the most recent period, up from $19.4 million in the immediately preceding quarter.
The company finished the first quarter of 2023 with cash, cash equivalents and marketable securities worth $328…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
